Anika Therapeutics (ANIK) Q2 FY26 earnings call: guidance and Q&A

Why does the raised full-year OEM guidance imply a sequential step-down in H2, and is it due to order timing or pricing/volume?

Management confirmed that H2 step-down is partly due to $1M-$2M favorable order timing in Q2 and a strong Q4 FY25 comparison. They are pleased with the overall OEM growth from previously flat/lower expectations, driven by US end-market performance. Pricing remains volatile but volume offsets it.

“I would say we did note in our prepared remarks that there is a little bit of favorability, probably between $1 million and $2 million just due to order timing in the second quarter. That does drive some of the sequential step down.”

asked by Anderson Schock · answered by Stephen Griffin

What are the main drivers for the improved gross margin, and are these mid-60s levels sustainable as a "new norm"?

Management confirmed that mid-60s gross margin is the new expectation, driven by lean transformation, eliminating waste, increasing throughput, improving yields, and specific manufacturing projects. They believe they are in the "early innings" of further improvements.

“I would say in short, yes. I think the mid 60s is where you could expect us to operate at. You know, the main drivers that you asked about, I noted in my remarks about the lean transformation. I mean, lean is all about eliminating waste and driving throughput and productivity.”

asked by Anderson Schock · answered by Stephen Griffin

Is the current pace of enrollment still on track for completion in 2026?

Management confirmed that enrollment is on track and completion is still expected "in and around year end" 2026, noting it's a small study with no concerns.

“In short, yes, I'd say the bioequivalent study is going as we would have expected. Enrollment remains on track and we did historically note that we'd expect it to be completed in and around year end and there's been no change to our expectations associated with that.”

asked by Anderson Schock · answered by Stephen Griffin

Given potential for less favorable OEM order timing in H2, will manufacturing productivity improvements be sufficient to maintain gross margin in the mid-60s?

Management reiterated that the mid-60s gross margin (around 64%) is sustainable for H2, despite some mix volatility. The gains from improved yields and throughput are structural and will continue to flow through, offsetting any H2 OEM order timing impact.

“I would say, you know, we've started the year at 64 and 65%. I mean, gross margin is never going to be in a straight linear line, as you know. So there is always some level of volatility, but implied in our guidance is that we will maintain sort of that 64% level.”

asked by Michael Petusky · answered by Stephen Griffin

What are the expectations for pricing trends for Monovisc/Orthovisc over the next 6-12 months, specifically regarding moderate vs. more than moderate declines?

Management expects pricing to remain a headwind, with modest declines, but volume growth is anticipated to more than offset this, leading to overall Monovisc revenue growth. Orthovisc is expected to decline. This dynamic is expected to continue.

“I would say the beneficial sort of results so far through the first half of the year and also what's implied in our guidance is that pricing will continue to be a headwind, but volume will more than offset it. And that's what we've seen thus far. So I think the modest decline in price that you noted is probably a fair representation of what we'd expect to see in the coming months and quarters.”

asked by Michael Petusky · answered by Stephen Griffin

Are there still meaningful opportunities for operational improvements beyond the "low-hanging fruit" already addressed, particularly in manufacturing, to support continued margin progress?

Management stated that while G&A restructuring (30% reduction) addressed low-hanging fruit, there is "a very long way to go" in manufacturing operations. The lean transformation is in its "early innings" and will take years to fully implement, driving both daily improvements and breakthrough projects.

“But as it relates to the operating expenses of the business, when we think about sort of manufacturing operations, I still think that there's a very long way to go. We're very much so in the early innings of driving this lean transformation. Those won't play out over 90 days, they take years.”

asked by Michael Petusky · answered by Stephen Griffin

Why has cash generation lagged other improvements, and what are the expectations for cash generation moving forward, particularly timing?

Management explained the lag is due to higher AR from large Q2 orders, expecting cash flow conversion in H2. They anticipate positive free cash flow in H2, following typical seasonality. Investments in inventory for safety stock also impacted cash. Stronger free cash flow is an expectation for FY27 and beyond.

“I think the reason for why you see a little bit of a lag from a cash flow perspective is we did see a larger amount of orders go out during the June time period. So AR is a little higher than normal, and we don't really ever have an AR issue in this business. So it's more so from a timing perspective, you wouldn't expect to see. some of that cash flow convert until the second half of the year.”

asked by Michael Petusky · answered by Stephen Griffin